EntityQ470517· pop 29· linked from 1,019 articles

Amgen

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.

Key facts

Company.name: Amgen Inc.
Company.former_names: Applied Molecular Genetics (1980–1983)
Company.logo: Amgen.svg
Company.logo_size: 250px
Company.image: Amgenheadquarters.jpg
Company.image_size: 250px
Company.image_caption: Headquarters in Thousand Oaks, California
Company.type: Public
Company.industry: Biotechnology
Company.revenue: (2025)
Company.operating_income: (2025)
Company.net_income: (2025)
Company.assets: (2025)
Company.equity: (2025)
Company.num_employees: 31,500 (2025)

via Wikipedia infobox

Article

14 sections

Contents

History
2000–2014
2015–2020
Acquisition history
Corporate affairs
Sponsorships
Philanthropy
Politics
Products
Products developed and then sold
Legal issues
See also
References
External links

The company's major products are Prolia and XGEVA (Denosumab) for treatment of osteoporosis and bone diseases ($6.7 billion in total 2024 revenues), Enbrel (Etanercept) for treatment of autoimmune diseases ($3.3 billion in 2024 revenues), Repatha (evolocumab) for treatment of hyperlipidemia ($2.3 billion in 2024 revenues), Otezla (apremilast) for treatment of psoriasis and psoriatic arthritis ($2.1 billion in 2024 revenues), Tepezza (teprotumumab) to treat Graves' ophthalmopathy ($1.8 billion in 2024 revenues), Evenity (romosozumab) to treat osteoporosis ($1.5 billion in 2024 revenues), Kyprolis (carfilzomib) to treat cancer ($1.5 billion in 2024 revenues), Nplate (romiplostim) to regulate platelet production ($1.4 billion in 2024 revenues), and Aranesp (darbepoetin alfa) to stimulate erythropoiesis ($1.3 billion in 2024 revenues).